Upload new images. The image library for this site will open in a new window.
Upload new documents. The document library for this site will open in a new window.
Show web part zones on the page. Web parts can be added to display dynamic content such as calendars or photo galleries.
Choose between different arrangements of page sections. Page layouts can be changed even after content has been added.
Move this whole section down, swapping places with the section below it.
Check for and fix problems in the body text. Text pasted in from other sources may contain malformed HTML which the code cleaner will remove.
Accordion feature turned off, click to turn on.
Accordion featurd turned on, click to turn off.
Change the way the image is cropped for this page layout.
Cycle through size options for this image or video.
Align the media panel to the right/left in this section.
Open the image pane in this body section. Click in the image pane to select an image from the image library.
Open the video pane in this body section. Click in the video pane to embed a video. Click ? for step-by-step instructions.
Remove the image from the media panel. This does not delete the image from the library.
Remove the video from the media panel.
Zhihao Zhuang has received a four-year, $792,000 Research Scholar Award from the American Cancer Society to support his lab's work.
Zhihao Zhuang, associate professor in the Department of Chemistry and Biochemistry at the University of Delaware, has received a four-year, $792,000 Research Scholar Award from the American Cancer Society.
The award will fund his labs ongoing work on a molecular approach to
boosting the effectiveness of drugs used to fight cancer.
Zhuang and his team recently reported a new finding in this research.
Their discovery that a deubiquitinase (or DUB) complex may be a key
regulator of the DNA damage response and a target for overcoming
resistance to platinum-based anticancer drugs was published in the
journal Nature Chemical Biology on Feb. 16.
Their work addresses two major pathways in the DNA damage response,
the translesion synthesis pathway and the Fanconi anemia pathway. Were
very encouraged by the fact that a single molecule is effective at
disrupting two essential DNA damage tolerance pathways, Zhuang says. This is very promising as a new weapon in the arsenal against cancer.
The letter informing Zhuang of the award said that he had been
selected to join an elite group of scientists and health care
professionals who have received awards from the American Cancer
Society. That select group includes researchers from Yale University,
the University of Pennsylvania, MIT, Stanford University, the University
of Chicago, and a number of other prestigious institutions across the
Support from the American Cancer Society is evidence that our
research is relevant to their mission of finding answers that save
lives, Zhuang says.
Although larger states like California, Illinois, and Pennsylvania
attract multiple research scholar awards from the American Cancer
Society each year, Zhuang and his team received the only one in Delaware
About the American Cancer Society
For more than 65 years, the American Cancer Society has funded
research and training of health professionals to investigate the causes,
prevention, and early detection of cancer, as well as new treatments,
cancer survivorship, and end of life support for patients and their
families. Since its founding in 1946, the American Cancer Societys
extramural research grants program has devoted more than $4 billion to
cancer research and has funded 47 researchers who have gone on to win
the Nobel Prize.
Move this whole section up, swapping places with the section above it.